- GlobeNewswire•18 days ago
Zutphen, The Netherlands - 31 December 2016 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announced during the year 2016 that it prepares a significant external funding to ...
- GlobeNewswire•2 months ago
ESPERITE N.V.: Stem Cells, Genetic Tests and Pharmaceuticals Patent granted to Cell Factory in Europe confirms great potential ...
- GlobeNewswire•3 months agoEsperite N.V. (ESP) expands extracellular vesicles (exosomes) products portfolio to include inflammatory bowel disease. The Cell Factory develops therapy for Crohn's disease.
Esperite N.V. (ESP) expands extracellular vesicles (exosomes) products portfolio to include inflammatory bowel disease. The Cell Factory develops therapy for Crohn`s disease. Esperite`s business unit The ...
ESP.AS : Summary for ESPERITE - Yahoo Finance
Esperite N.V. (ESP.AS)
Amsterdam - Amsterdam Delayed Price. Currency in EUR
Add to watchlist
|Bid||1.33 x 75700|
|Ask||1.35 x 173600|
|Day's Range||1.38 - 1.42|
|52 Week Range||1.15 - 2.79|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|